Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc develops and manufactures therapeutic medical devices and healthcare technology for chronic diseases and procedural care. Its news commonly covers regulatory clearances and CE marks, product launches, clinical data, acquisitions, and financial results across cardiovascular, cardiac rhythm management, cranial and spinal technologies, surgical navigation, robotics, and ablation systems.
Recent company updates include the Stealth AXiS™ surgical system for planning, navigation, and robotics; the Affera™ mapping and ablation system with Sphere-9™ and Sphere-360™ catheters; the OmniaSecure™ defibrillation lead; and the completed CathWorks acquisition, including the FFRangio® System for coronary artery disease assessment.
MiniMed Group (Nasdaq: MMED) began trading March 6, 2026 on the Nasdaq Global Select Market following an oversubscribed IPO.
The offering was described as the second largest IPO in medtech history and positions MiniMed to operate as a standalone company, while supporting Medtronic (NYSE: MDT)'s capital-focus strategy amid geopolitical market uncertainty.
MiniMed Group (planned Nasdaq: MMED) priced an initial public offering of 28,000,000 shares at $20.00 per share, with expected Nasdaq trading to begin March 6, 2026 and closing of the offering expected March 9, 2026, subject to customary conditions.
MiniMed granted underwriters a 30-day option for up to 4,200,000 additional shares. Upon completion, Medtronic is expected to retain approximately 90.03% ownership (88.70% if the over-allotment is fully exercised). Proceeds will fund general corporate purposes and may repay intercompany debt to Medtronic.
Medtronic (NYSE: MDT) announced a cash dividend of $0.71 per ordinary share for the fourth quarter of fiscal 2026. The board approved the dividend on March 5, 2026, payable April 17, 2026, to shareholders of record at the close of business on March 27, 2026.
Medtronic noted this quarterly declaration aligns with its May 2025 dividend increase and highlighted its 48-year streak of consecutive annual dividend increases as a member of the S&P 500 Dividend Aristocrats.
Medtronic (NYSE:MDT) announced that Thierry Piéton, executive vice president and chief financial officer, will appear in fireside chats at two investor conferences on March 10–11, 2026.
Live webcasts will be available via the company's investor events page, with archived recordings posted later the same day.
Medtronic (NYSE: MDT) launched the MiniMed Go™ Smart MDI system with the Simplera™ sensor across Europe beginning Feb 2026. The system integrates InPen™ smart insulin pen and Simplera™ CGM into one app, offering real-time dose calculation, missed-dose alerts, CareLink Clinic MDI reports, and expanded pediatric labeling.
Rollout is gradual across Europe; Instinct Go™ compatibility is pending CE mark and Simplera™ compatibility in the U.S. is under FDA review.
MiniMed Group (proposed Nasdaq: MMED) launched its IPO roadshow on Feb 24, 2026, offering 28,000,000 shares with an expected price range of $25.00–$28.00 per share and a 30-day over-allotment option for 4,200,000 shares.
Upon completion Medtronic (NYSE: MDT) would retain approximately 90.03% ownership (or 88.70% if the over-allotment is exercised). Proceeds will fund general corporate purposes, repay intercompany debt, and provide additional consideration to Medtronic. A Form S-1 has been filed but is not yet effective.
Medtronic (NYSE: MDT) reported Q3 FY26 revenue of $9.017 billion, up 8.7% as reported and 6.0% organic, with GAAP diluted EPS of $0.89 and non-GAAP diluted EPS of $1.36.
Notable drivers: Cardiac Ablation Solutions +80% (U.S. +137%), Diabetes organic +8.3%, CE Mark for Sphere-360, U.S. FDA clearances for Hugo robotic surgery and Stealth AXiS, and two M&A deals (CathWorks, Anteris). Company reiterated FY26 organic revenue ~5.5% and non-GAAP EPS guidance of $5.62–$5.66 (tariff impact ~$185M).
Medtronic (NYSE:MDT) announced that the first U.S. commercial surgical case using the FDA-cleared Hugo™ robotic-assisted surgery (RAS) system was performed at Cleveland Clinic on Feb. 17, 2026, where a robotic-assisted prostatectomy was completed and the patient discharged the next day.
The Hugo RAS system completed the Expand URO IDE study meeting primary safety and effectiveness endpoints and is available in more than 35 countries; Medtronic plans indication expansion into gynecologic and general surgery.
Medtronic (NYSE: MDT) announced FDA clearance of the Stealth AXiS™ surgical system on Feb 13, 2026, a unified platform that integrates planning, navigation and robotics for spine surgery.
The system features LiveAlign™ segmental tracking for real-time anatomic motion visualization, a modular robotic design for staged deployment, and architecture intended to support future cranial and ENT applications pending 510(k) clearance.
Medtronic (NYSE: MDT) will report third-quarter fiscal 2026 results on Tuesday, February 17, 2026, covering the quarter ended January 23, 2026.
A news release with summary financial information will be issued at ~5:45 a.m. Central Standard Time, followed by a video webcast at 7:00 a.m. CST. Replay and transcript will be posted within 24 hours.